Seroprevalence of SARS-CoV-2 in Parkinson's Disease Patients: A Case-Control Study

Affiliations

¹ Functional Neurosurgery Research Center, Shohada Tajrish Comprehensive Neurosurgical Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
² Department of Functional Neurosurgery Medical School, Isfahan University of Medical Science, Isfahan, Iran.

Mehri Salari et al. Mov Disord. 2021 Apr.

. 2021 Apr;36(4):794-795.

doi: 10.1002/mds.28580. Epub 2021 Mar 17.

¹ Functional Neurosurgery Research Center, Shohada Tajrish Comprehensive Neurosurgical Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
² Department of Functional Neurosurgery Medical School, Isfahan University of Medical Science, Isfahan, Iran.

No abstract available

Keywords: Parkinson's disease; SARS-CoV-2; seroprevalence.

Cited by

Prevalence and outcomes of Covid-19 in Parkinson's disease: Acute settings and hospital.
Fearon C, Fasano A. Fearon C, et al. Int Rev Neurobiol. 2022;165:35-62. doi: 10.1016/bs.irn.2022.03.001. Epub 2022 Apr 20. Int Rev Neurobiol. 2022. PMID: 36208906 Free PMC article.
Movement Disorders and SARS-CoV-2.
Fung WKW, Fasano A, Fearon C. Fung WKW, et al. Mov Disord Clin Pract. 2022 Dec 7;10(Suppl 2):S9-S17. doi: 10.1002/mdc3.13615. eCollection 2023 Aug. Mov Disord Clin Pract. 2022. PMID: 37637980 Free PMC article. No abstract available.

1. Bossa F, Carparelli S, Latiano A, Palmieri O, Tavano F, Panza A, et al. Impact of the COVID‐19 outbreak and the serum prevalence of SARS‐CoV‐2 antibodies in patients with inflammatory bowel disease treated with biologic drugs. Dig Liver Dis [Internet] 2021;53:277–282. 10.1016/j.dld.2020.12.120 - DOI - PMC - PubMed
1. Behrens GMN, Cossmann A, Stankov MV, Schulte B, Streeck H, Förster R, et al. Strategic anti‐SARS‐CoV‐2 serology testing in a low prevalence setting: the COVID‐19 contact (CoCo) study in healthcare professionals. Infect Dis Ther 2020;9(4):837–849. - PMC - PubMed
1. Papa SM, Brundin P, Fung VSC, Kang UJ. Impact of the COVID‐19 pandemic on Parkinson's disease and movement disorders the COVID‐19 pandemic is the PD population particularly vulnerable during the COVID‐19 pandemic ? COVID‐19 and neurological. Mov Disord 2020;35(3):711–715. - PMC - PubMed
1. Yu Y, Travaglio M, Popovic R, Santos Leal N, Miguel Martins L. Alzheimer's and Parkinson's diseases predict different COVID‐19 outcomes, a UK Biobank study. Geriatrics 2021;26:10. - PMC - PubMed
1. Artusia CA, Romagnoloa A, Imbalzanoa G, Marchetb A, Zibettia M, Mario Giorgio Rizzonea LL. COVID‐19 in Parkinson's disease: report on prevalence and outcome. Parkinsonism Relat Disord 2020;80:7–9. - PMC - PubMed